【2h】

Vulvovaginal Atrophy

机译:外阴阴道萎缩

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vulvovaginal atrophy (VVA) is a common and underreported condition associated with decreased estrogenization of the vaginal tissue. Symptoms include dryness, irritation, soreness, and dyspareunia with urinary frequency, urgency, and urge incontinence. It can occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase, during which the prevalence is close to 50%. Clinical findings include the presence of pale and dry vulvovaginal mucosa with petechiae. Vaginal rugae disappear, and the cervix may become flush with the vaginal wall. A vaginal pH of 4.6 or more supports the diagnosis of VVA. Even while taking systemic estrogen, 10% to 20% of women may still have residual VVA symptoms. Breast cancer treatment increases the prevalence of VVA because the surgical, endocrine, and chemotherapeutic agents used in its treatment can cause or exacerbate VVA. Local estrogen treatment for this group of women remains controversial.
机译:阴道阴道萎缩(VVA)是一种常见且报告不足的疾病,与阴道组织的雌激素减少有关。症状包括干燥,刺激,酸痛和排尿困难,尿频,尿急和急迫性尿失禁。它可以在女性生命周期中的任何时间发生,尽管更常见于绝经后阶段,在此阶段,患病率接近50%。临床发现包括浅色和干燥的阴道阴道粘膜伴有瘀斑。阴道皱纹消失,子宫颈可能与阴道壁齐平。阴道pH值为4.6或更高可支持VVA的诊断。即使服用全身性雌激素,仍有10%至20%的女性仍有VVA残留症状。乳腺癌治疗会增加VVA的患病率,因为在其治疗中使用的外科,内分泌和化学治疗剂会引起或加剧VVA。对于这组妇女的局部雌激素治疗仍存在争议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号